The AIDS Clinical Trials Group (ACTG) has been at the forefront of clinical research to advance HIV therapeutics and improve the health of patients living with HIV/AIDS for 25 years. Rigorous scientific research conducted by the ACTG has laid the cornerstones for current HIV treatment guidelines. In this application for the competitive renewal of the ACTG we propose a transformative research agenda that draws on an international consortium of leading clinical and laboratory HIV Investigators in collaboration with a world-class Statistics and Data Management Center to design and conduct innovative interventional clinical trials that will significantly reduce the global burden of disease due to HV, TB and hepatitis. A newly restructured Leadership and Operations Center (LOC) is proposed to provide scientific leadership and fiscal and organizational management of the ACTG. The ACTG Executive Committee (AEC) will serve as the overarching governing body of the network. Transformative Science Groups will oversee the development and execution of the ACTG research agenda, which will be coordinated and prioritized by the Scientific Agenda Steering Committee (SASC). Protocol development, implementation, training and network evaluation will be facilitated by the Network Coordinating Center at Social &Scientific Systems, Inc. The LOC financial management group at Brigham and Women's Hospital (BWH) will oversee resource management and protocol fund distribution at the direction of the AEC. The LOC will assure the engagement of Community in all aspects of the ACTG, and will coordinate communication between all three components of the network.
Specific aims of this proposal include: 1) to identify strategies to cure and/or achieve a functional cure for HIV;2) to improve the diagnosis and treatment of tuberculosis, especially in those co-infected with HIV;3) to identify strategies o cure Infectious hepatitis;4) to prevent or improve the treatment of, non-infectious co-morbidities and evaluate novel Interventions targeting HIV Infection;5) to Investigate and improve oral health outcomes in persons with HIV/AIDS;and 6) to improve the treatment for viral related malignancies In HIV-infected adults.
The studies proposed in this application will have a direct beneficial effect on the health of millions of people worldwide who are infected with or at risk for HIV, tuberculosis and viral hepatitis, transforming the health of patients with these infections. The clinical research conducted by the ACTG will lead to significantly reducing morbidity and mortality, particularly among populations disproportionately affected by HIV/AIDS.
|Luz, Paula M; Morris, Bethany L; Grinsztejn, Beatriz et al. (2015) Cost-effectiveness of genotype testing for primary resistance in Brazil. J Acquir Immune Defic Syndr 68:152-61|
|Dooley, Kelly E; Denti, Paolo; Martinson, Neil et al. (2015) Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis 211:197-205|
|Vardhanabhuti, Saran; Taiwo, Babafemi; Kuritzkes, Daniel R et al. (2015) Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia. Antivir Ther 20:73-6|
|Bennetto-Hood, Chantelle; Tabolt, Glenn; Savina, Paul et al. (2014) A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 945-946:225-32|
|Li, Jonathan Z; Gallien, Sebastien; Ribaudo, Heather et al. (2014) Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS 28:181-6|
|Zvada, Simbarashe P; Denti, Paolo; Donald, Peter R et al. (2014) Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. J Antimicrob Chemother 69:1339-49|
|Moholisa, Retsilisitsoe R; Schomaker, Michael; Kuhn, Louise et al. (2014) Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther 19:399-406|
|Smith, Kimberly Y; Tierney, Camlin; Mollan, Katie et al. (2014) Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis 58:555-63|
|Fitzgibbon, Joseph E; Wallis, Carole L (2014) Laboratory challenges conducting international clinical research in resource-limited settings. J Acquir Immune Defic Syndr 65 Suppl 1:S36-9|
|Weinberg, Adriana; Bosch, Ronald; Bennett, Kara et al. (2014) Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS. J Acquir Immune Defic Syndr 66:25-32|
Showing the most recent 10 out of 101 publications